Drugs / Ac-Lintuzumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03705858 | Feb 2019 | acute myeloid leukemia | Joseph Jurcic | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ac-Lintuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03705858 ↗ |
| Modality | Monoclonal antibody | “anti-CD33 monoclonal antibody lintuzumab” NCT03705858 ↗ |
| Route | Intravenous | “225Ac-lintuzumab will administered at 4 dose levels: 0.25, 0.5, 0.75 or 1 µCi/kg intravenously (IV) over 30 ± 10 minutes.” NCT03705858 ↗ |
| Target | CD33 | “anti-CD33 monoclonal antibody” NCT03705858 ↗ |